Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-07-03T11:12:59.522Z Has data issue: false hasContentIssue false

56 - Infections in patients with advanced cancer

Published online by Cambridge University Press:  04 August 2010

Rudolph M. Navari
Affiliation:
Walther Cancer Research Center, University of Notre Dame, Notre Dame, IN
Michael J. Fisch
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Eduardo Bruera
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Get access

Summary

Introduction

Patients with advanced or terminal cancer are at high risk for infections as a result of the underlying disease, a poor nutritional state, and/or a direct suppression of the hematological system due to chemotherapy or radiation treatments. An infectious complication may occur due to an alteration in the phagocytic, cellular, or humoral immunity, an alteration or breach of their skin or mucosal defense barriers, indwelling catheters, or a splenectomy. A high index of suspicion, a consideration of the empirical institution of antimicrobials, an awareness of the possibility of unusual infectious agents, and a constant surveillance of the hematological status of the patients are necessary in order to provide optimal management of infections in this patient population.

This review will consider the initial evaluation of fever, the use of antimicrobial agents, the predominant organisms associated with infection, and the management of infectious complications in this specific patient population. Special consideration and discussion will be given to patients receiving hospice and palliative care.

Evaluation of fever

In patients with advanced cancer, fever is very common and it may or may not have an infectious etiology. It must be noted that fever may be the only manifestation of an infection in an immunocompromised patient and there is no pattern of fever that can be used to definitively rule out an infectious etiology. Fever may also be modified by the use of specific medications such as corticosteroids or nonsteroidal anti-inflammatory agents.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ahronheim, J C, Morrison, R S, Baskin, S A. Treatment of the dying in the acute care hospital. Arch Intern Med 1996;156:2094–100CrossRefGoogle ScholarPubMed
Bruera, E. Intractable pain in patients with advanced head and neck tumors: a possible role of local infection. Cancer Treat Rep 1986;70:691–2Google ScholarPubMed
Finberg, R W, Talcott, J A. Fever and neutropenia – how to use a new treatment strategy. N Engl J Med 1999;341:362–3CrossRefGoogle ScholarPubMed
Klastersky, J. Empirical treatment of sepsis in neutropenic patients. Int J Antimicrob Agents 2000;16:131–3CrossRefGoogle ScholarPubMed
Klastersky, J, Paesmans, M, Rubenstein, E B. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenia cancer patients. J Clin Oncol 2000;18:3038–51CrossRefGoogle ScholarPubMed
Navari, R M, Daskal, F. Antibiotic use in advanced cancer patients receiving end of life palliative care. ASCO 2001;20:1554Google Scholar
Pereira, J, Watanabe, S, Wolch, G. A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit. J Pain Symptom Manage 1998;16:374–81CrossRefGoogle ScholarPubMed
Pizzo, P A. Fever in immunocompromised patients. N Engl J Med 1999;341:893–900CrossRefGoogle ScholarPubMed
Steinberg, J P, Clark, C C, Hackman, B O. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996;23:255–9CrossRefGoogle ScholarPubMed
The choice of antibacterial drugs. Med Letter 2001;43:69–78
Vazquez, J A, Lynch, M, Boikov, D, Sobel, J D. In vitro activity of a new pneumocardin antifungal, L-743,872, against azole-susceptible and resistant Candida species. Antimicrob Agents Chemother 1997;41:1612–14Google ScholarPubMed
Vitetta, L, Kenner, D, Sali, A. Bacterial infections in terminally ill hospice patients. J Pain Symptom Manage 2000;20:326–34CrossRefGoogle ScholarPubMed
Walsh, T J, Finberg, R W, Arndt, C. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764–71CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×